Pharmacology to practice: The similarities and differences of drugs targeting CD20 Book Section
| Authors: | Lue, J. K.; Cheson, B. D. |
| Editors: | O'Connor, O. A.; Ansell, S. M.; Gribben, J. G. |
| Article/Chapter Title: | Pharmacology to practice: The similarities and differences of drugs targeting CD20 |
| Abstract: | Rituximab was the first monoclonal antibody to gain FDA approval for cancer therapy. Anti-CD20 monoclonal antibodies can be classified into Type I and Type II categories. Obinutuzumab may be preferred in some indications, such as CLL. Novel bispecific antibodies that simultaneously engage CD20-CD3 are promising for the treatment of B-cell NHL. © 2024 John Wiley & Sons Ltd. |
| Keywords: | pharmacology; ofatumumab; bispecific antibodies; obinutuzumab; ublituximab; drugs targeting cd20; monoclonal antibody development |
| Book Title: | Precision Cancer Therapies: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice |
| Volume: | 2 |
| ISBN: | 9781119824541 |
| Publisher: | Wiley Blackwell |
| Publication Place: | Hoboken, NJ |
| Date Published: | 2024-01-01 |
| Start Page: | 22 |
| End Page: | 39 |
| Language: | English |
| DOI: | 10.1002/9781119824572.ch3 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 3 -- Source: Scopus |
